In a mouse model of Parkinson’s disease animals show signs of inflammation in the gut, and treatment with cell therapies that reduce this inflammation help to ease symptoms of Parkinson’s, according to a new study. These results suggest that inflammatory conditions in the gut may contribute to the development…
News
The U.S. Food and Drug Administration (FDA) has granted NeuroOne Medical Technologies clearance to market its Evo stereoelectroencephalography (sEEG) electrode technology for temporary use of less than 30 days. The device — previously cleared by the FDA for use of less than one day — is used to measure…
People with Parkinson’s disease have generally positive attitudes toward using therapies derived from human embryos, according to a new study based on interviews with patients in Sweden. The study, “Patients’ views on using human embryonic stem cells to treat Parkinson’s disease: an interview study,” was published in BMC Medical Ethics.
To better care for the growing number of people with Parkinson’s disease and their families, the Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program. The two-year fellowship supports medical centers in training a new generation of…
A therapeutic mix of exercise, cognitive stimulation and social activity — known as environmental enrichment — eased Parkinson’s disease symptoms and protected brain cells in a mouse model, though to a greater extent in early disease stages, a study reported. Benefits were notably less potent in animals with more advanced…
XPhyto Therapeutics’ generic version of the Neupro patch for Parkinson’s disease is showing that its active ingredient, rotigotine, can be absorbed through the skin in ways similar to the brand-name product, the company announced. Findings, in work using skin from human cadavers and an optimized formula for the generic patch, support…
Former caregivers could serve as a helpful resource in supporting current caregivers of people with Parkinson’s disease, a study reported. The intent is to “provide guidance for developing peer-to-peer support programs, incorporating former carers,” its researchers wrote. The study, “Using former carers’ expertise in peer support for…
BioVie has completed enrollment for a Phase 2 clinical trial evaluating the safety and efficacy of its experimental oral therapy NE3107 in people with Parkinson’s disease. “To date, we have seen no drug-related adverse events [side effects],” Cuong Do, BioVie’s president and CEO, said in a company press…
The University of Arkansas for Medical Sciences (UAMS) is offering complimentary vocal music workshops to patients with neurodegenerative disorders such as Parkinson’s disease. The workshops, which begin Oct. 26, will address patients’ physical, cognitive, and emotional needs, and are designed to teach patients how the voice works, how…
People who go on to develop a neurodegenerative disease such as Parkinson’s may experience poorer overall health and show signs of disease many years before they get diagnosed, according to a study from the University of Cambridge in the U.K. For those with Parkinson’s, grip strength in both hands…
Recent Posts
- Balancing safety and individual autonomy in Parkinson’s disease
- Patient visits wrap up in Parkinson’s trial of oral bezisterim therapy
- Brain pathway shows potential for slowing Parkinson’s, but only in females
- Parkinson’s disease forced our family to say the quiet parts out loud
- First US state passes ban on paraquat, herbicide tied to higher Parkinson’s risk